IP Library Granted Patent US 7,034,145
Granted Patent B2
US 7,034,145 · App. 10/933,855 · Granted Apr 25, 2006

Directionally cloned random cDNA expression vector libraries, compositions and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,034,145
App. No.
10/933,855
Granted
Apr 25, 2006
Kind
B2
Abstract

The present invention provides random cDNA expression vector libraries, comprising expression vectors which comprise random cDNAs positioned in sense orientation. Also provided are random cDNA expression vector libraries, comprising expression vectors which comprise random cDNAs positioned in antisense orientation. Methods for producing these libraries through directional cloning of random cDNAs are also provided. Also provided herein are methods of using these libraries to screen for agents capable of modulating cell phenotype in desirable ways.

Claims (10)

1. A composition comprising combinable reagents for making a directionally cloned cDNA library, comprising:

a primer having at its 5′ terminus a first nucleotide sequence of a 3′ portion of a restriction site for an infrequently cutting restriction endonuclease; and

a double stranded adaptor having a second nucleotide sequence of a 5′ end of said restriction site for said infrequently cutting restriction endonuclease.

2. The composition of claim 1 , wherein said first and second nucleotide sequences, when ligated together, form a complete sequence of a restriction site for said infrequently cutting restriction endonuclease.

3. The composition of claim 1 , wherein said infrequently cutting restriction endonuclease is Sfi1, BstAP1, PfiM1, Mwo1 or AlwN1.

4. The composition of claim 3 , wherein said infrequently cutting restriction endonuclease is Sfi1.

5. The composition of claim 1 , wherein said primer contains a CC at its 5′ terminus.

6. The composition of claim 1 , wherein said primer is a random primer.

7. The composition of claim 6 , wherein said random primer contains 4 to 10 random nucleotides at its 3′ end.

8. The composition of claim 1 , wherein said primer comprises oligodT.

Assignments (2)
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2004
From: SHEN, MARY; YU, SIMON; WU, XIAN; PAYAN, DONALD
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 015771/0219 →